Inclusion Criteria:

- Early breast cancer: histopathologically confirmed diagnosis, maximum tumour stage T1
and T2, therefore diameter < 5 cm, unifocal tumour or multifocal tumour Grading
G1-G3, invasive ductal and / or invasive lobar carcinoma ≤ 5 cm diameter

- Indicated sentinel lymph node biopsy as part of the patient's routine management for
breast cancer

- Age: 18 - 80 years, inclusive

- Gender: male and female

- BMI: ≤ 30

- Non-smoker (for at least the previous 3 months)

- General operability

- Intact site-specific anatomy at the concerned breast and /or axilla for ensuring an
adequate lymphangiography

- Performance of investigations with radioactive traced iodide at least 1 week before
and 1 week after ICG application

- No clinically significant findings in the routine blood examinations

- Female subjects with childbearing potential must have a negative pregnancy test prior
Tc application and must be either at least two years postmenopausal or using a highly
effective mean of birth control (birth control that, alone or in combination, result
in a low failure rate of less than 1 percent per year when used consistently and
correctly):

- hormonal method of contraception,

- surgical sterility,

- double barrier methods,

- intrauterine contraceptive device,

- lifestyle with a personal choice of abstinence,

- bilateral vasectomy of sexual partner at least 3 months prior to enrolment in
combination with barrier methods

- Willing and able to complete screening and study procedures, as described in the
protocol

- Signed written informed consent to participate in this clinical trial

Exclusion Criteria:

- Breast cancer: stage T3 or T4 carcinoma, inflammatory or exulcerated mamma carcinoma

- Former operation in axilla

- Any previous radiotherapy at the concerned breast and / or axilla and / or chestwall

- Definite lymph node metastases (ultrasound and / or fine-needle aspiration) (definite
nodal positive patients in fine-needle aspiration)

- Contraindication for technetium imaging

- History of allergy or hypersensitivity against the investigational medicinal products
(its active substance or ingredients)

- History of intolerability to ICG-Pulsion during a previous injection, as this may
lead to serious anaphylactic reactions

- History of allergic diseases / hypersensitivities, unless the investigator considers
the allergic disease as clinically irrelevant for the purpose of this clinical trial

- Allergy to iodine or to shellfish

- Any other contraindication to one of the investigational medicinal products as
described in their Summary of Product Characteristics

- Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or
disseminated autonomies of the thyroid gland

- Advanced renal impairment (creatinine > 1,5mg/dl)

- Complete lymphatic obstruction

- All clinically relevant internal medicinal diseases, cardiac or renal that could
impair the outcome of the clinical trial or that in the investigator's mind are not
compatible with participation for medical reasons

- Acute inflammatory or febrile illness

- Evidence of local inflammation at the site of surgery

- Concurrent medication or any medication during the 2 weeks preceeding the enrolment
which reduce or increase the extinction of ICG (i.e. anticonvulsants, haloperidol)

- Current or recent history of illicit drug or alcohol abuse, or dependence as defined
as the continued use of alcohol or drugs despite the development of social, legal, or
health problems

- Psychiatric or cognitive impairment that, in the opinion of the investigator, would
interfere with the subject's ability to comply with the study requirements (e.g.
Alzheimer's disease)

- Pregnancy, breastfeeding

- Inability to understand the nature and the extent of the trial and the procedures
required

- Missing signed written informed consent to participate in the clinical trial

- Participation in a drug trial during the whole clinical trial